Sophie Rakete

Mrs. Sophie Rakete


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2022 in Food Chemistry
Verified
Journal Article
Open access
JKJulia Kokesch-Himmelreich
Julia Kokesch-Himmelreich
OWOliver Wittek
Oliver Wittek
ARAlan M. Race
Alan M. Race
SRSophie Rakete
Sophie Rakete
CSClaus Schlicht
Claus Schlicht
ARAndreas Römpp
Andreas Römpp
Mass Spectrometry imaging (MS imaging) provides spatial information for a wide range of compound classes in different sample matrices. We used MS imaging to investigate the distribution of components in fresh and processed food, including meat, dairy and bakery products. The MS imaging workflow was optimized to cater to the specific properties and challenges of the individual samples. We successfully detected highly nonpolar and polar constituents such as beta-carotene and anthocyanins, respectively. For the first time, the distributions of a contaminant and a food additive were visualized in processed food. We detected acrylamide in German gingerbread and investigated the penetration of the preservative natamycin into cheese. For this purpose, a new data analysis tool was developed to study the penetration of analytes from uneven surfaces. Our results show that MS imaging has great potential in food analysis to provide relevant information about components' distributions, particularly those underlying official regulations.

1 April 2021 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
SRSophie Rakete
Sophie Rakete
CSCarina Schuster
Carina Schuster
MPMichael Paal
Michael Paal
MVMichael Vogeser
Michael Vogeser

14 June 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
ULUwe Liebchen
Uwe Liebchen
SRSophie Rakete
Sophie Rakete
MVMichael Vogeser
Michael Vogeser
FAFlorian M. Arend
Florian M. Arend
CKChristina Kinast
Christina Kinast
MPMichael Paal
Michael Paal
Several studies have addressed the poor stability of meropenem in aqueous solutions, though not considering the main degradation product, the open-ring metabolite (ORM) form. In the present work, we elucidate the metabolic fate of meropenem and ORM from continuous infusion to the human bloodstream. We performed in vitro infusate stability tests at ambient temperature with 2% meropenem reconstituted in 0.9% normal saline, and body temperature warmed buffered human serum with 2, 10, and 50 mg/L meropenem, covering the therapeutic range. We also examined meropenem and ORM levels over several days in six critically ill patients receiving continuous infusions. Meropenem exhibited a constant degradation rate of 0.006/h and 0.025/h in normal saline at 22 °C and serum at 37 °C, respectively. Given that 2% meropenem remains stable for 17.5 h in normal saline (≥90% of the initial concentration), we recommend replacement of the infusate every 12 h. Our patients showed inter-individually highly variable, but intra-individually constant molar ORM/(meropenem + ORM) ratios of 0.21–0.52. Applying a population pharmacokinetic approach using the degradation rate in serum, spontaneous degradation accounted for only 6% of the total clearance.